Literature DB >> 16472832

Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test.

Romeo D Ando1, Anita Benko, Linda Ferrington, Eszter Kirilly, Paul A T Kelly, Gyorgy Bagdy.   

Abstract

The acute effects of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) on anxiety-related behaviours were studied using indices of social interaction in Dark Agouti (DA) both drug naive rats and those pretreated with MDMA (15 mg/kg i.p.) 3 weeks earlier. The functional neuroanatomy of these MDMA effects was visualised using 2-deoxyglucose imaging of local cerebral glucose use (LCMRglu), whilst MDMA-induced serotonergic neurotoxicity was measured by radioligand binding with [3H]paroxetine. Acute MDMA alone markedly decreased most typical elements of social interaction but increased adjacent lying, a behaviour that also contains social elements. In animals pre-exposed to MDMA, decreased [3H]paroxetine binding indicated serotonergic terminal depletion, and in these animals significant increases in locomotor activity, exploratory behaviour and aggressive behaviour were found. Both behavioural effects and also the metabolic activation induced by acute MDMA were potentiated in rats previously exposed to the drug. In conclusion, a single dose of MDMA caused marked changes in social behaviour acutely that might be interpreted either as a decrease or increase in anxiety. Three weeks after MDMA a behavioural disinhibition similar to psychomotor agitation, a symptom connected to depression or mania, and a sensitization to the acute effects of MDMA are apparent in both the behavioural and brain metabolic effects of the drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472832     DOI: 10.1016/j.neuropharm.2005.12.010

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

2.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

3.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

4.  Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Authors:  Linnet Ramos; Callum Hicks; Richard Kevin; Alex Caminer; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2013-05-16       Impact factor: 7.853

Review 5.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

6.  MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology.

Authors:  P Sáez-Briones; A Hernández
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

7.  Social Cognition and Interaction in Chronic Users of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy").

Authors:  Michael D Wunderli; Matthias Vonmoos; Lorena Treichler; Carmen Zeller; Isabel Dziobek; Thomas Kraemer; Markus R Baumgartner; Erich Seifritz; Boris B Quednow
Journal:  Int J Neuropsychopharmacol       Date:  2018-04-01       Impact factor: 5.176

8.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

9.  Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination.

Authors:  Sami Ben Hamida; Erin Plute; Sonia Bach; Christine Lazarus; Antoine Tracqui; Christian Kelche; Anne Pereira de Vasconcelos; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

10.  Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats.

Authors:  Peter Petschner; Viola Tamasi; Csaba Adori; Eszter Kirilly; Romeo D Ando; Laszlo Tothfalusi; Gyorgy Bagdy
Journal:  BMC Genomics       Date:  2018-08-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.